Dr. Noura Choudhury is a highly skilled and compassionate medical oncologist dedicated to providing exceptional care to patients with thoracic and head and neck malignancies. Dr. Choudhury is also a clinical and translational investigator, with a particular focus in small cell lung cancer. Her expertise is grounded in years of dedicated experience, which allows her to provide personalized care that addresses each patient’s unique needs.
Using a patient-centered approach to care, Dr. Choudhury ensures that each treatment plan is tailored to her patients’ specific condition, symptoms, lifestyle and healthcare goals. By integrating the latest advancements in cancer care, she strives to enhance the overall well-being of her patients. She has expertise in standard of care treatments such as chemotherapy, immunotherapy and targeted therapies, as well as novel therapeutics such as bispecific T cell engagers, antibody drug conjugates and bispecific antibodies.
In additional to her clinical work, Dr. Choudhury actively develops clinical trials, contributing to the advancement of cancer treatment. She is national Principal Investigator of an investigator-initiated National Cancer Institute (NCI) phase I/II study in small cell lung cancer, as well as the principal investigator of multiple phase I clinical trials, including first-in-human studies of novel therapeutics. She is a translational physician scientist who strives to bring discoveries in the laboratory to patients in the clinic. Her involvement in leading-edge research allows her to offer her patients access to new therapies and innovative treatments, improving their outcomes and quality of life. Her work also focuses on identifying mechanisms of response and resistance to novel treatment strategies. She is an author on numerous publications, with her work has been published in The Lancet, Clinical Cancer Research, Journal of Thoracic Oncology, Journal of Clinical Oncology, Annals of Oncology, among others.
Early dynamics of circulating tumor HPV-DNA with neoadjuvant chemotherapy and response-adapted de-escalation in human papillomavirus-associated oropharyngeal cancer.
Early dynamics of circulating tumor HPV-DNA with neoadjuvant chemotherapy and response-adapted de-escalation in human papillomavirus-associated oropharyngeal cancer. Clin Cancer Res. 2025 May 27.
PMID: 40423530
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer. Clin Cancer Res. 2024 Nov 15; 30(22):5042-5052.
PMID: 39287821
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer.
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer. Clin Cancer Res. 2024 Sep 03; 30(17):3697-3703.
PMID: 38940666
The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung Cancer.
The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 09 01; 29(17):3418-3428.
PMID: 37223888
Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation.
Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation. J Thorac Oncol. 2023 09; 18(9):1222-1232.
PMID: 37210008
Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors.
Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors. Clin Cancer Res. 2022 11 01; 28(21):4649-4659.
PMID: 36044468
Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib.
Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib. JCO Precis Oncol. 2021; 5.
PMID: 34250398
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Clin Cancer Res. 2021 05 15; 27(10):2899-2909.
PMID: 33685866
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. Clin Cancer Res. 2021 05 15; 27(10):2920-2927.
PMID: 33685865
Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center.
Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center. Oncotarget. 2019 Oct 08; 10(56):5817-5823.
PMID: 31645901